AbilityPharma Secures Funding of €7M for Progressing Phase 2b Trials of ABTL0812, an Autophagy-Stimulating Drug, in Treating Spread-Out Pancreatic Cancer.

Novo Nordisk has excelled in research and development, aiding over 40 million chronic disease patients globally.

Ranok Therapeutics broadens its clinical trials for its BRD4 protein degradation agent RNK05047, now including tests in China.

Budesonide, a small molecule drug with a strong ability to bind to the glucocorticoid receptor (GR) as an agonist, was approved as early as 1981 and has been on the market for more than 40 years.

ASLAN Pharmaceuticals Offers Update on TREK-DX Research and Emphasizes Eblasakimab's Effectiveness for Patients with Atopic Dermatitis Previously Treated with Dupilumab.

In January, Oricell Therapeutics announced U.S. FDA approval for the IND application of OriCAR-017 to treat relapsed/refractory multiple myeloma (R/R MM).

MoonLake reveals notable advancements using Nanobody® sonelokimab over a six-month period for treating active psoriatic arthritis (PsA), along with other crucial updates during its research and development event.

Prazosin, a minuscule molecule drug, exhibits antagonistic properties towards α1A-AR, α1B-AR, and α1D-AR receptors.

Latest findings from the second phase of testing indicate that amlitelimab may be a top-performing contender for sustained treatment effectiveness in managing eczema.

Domain Therapeutics secured nearly €10M from the French National Research Agency via the "Hospital-University Health Research SPRINT Alliance" in January, to advance precision medicine and bring their lead drug DT-7012 to clinical trials.

RemeGen Showcases Study of Unique Disitamab Vedotin (RC48) in Treating Cervical Cancer through Verbal Presentation at 2024 ESGO Event.

Digoxin, a small molecule, is known for inhibiting Na/K-ATPase, increasing intracellular calcium, and thus enhancing heart function.